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ABSTRACT
Several different mRNAs can be produced from a
given pre-mRNA by regulated alternative splicing,
or as the result of deregulations that may lead to
pathological states. Analysing splicing patterns is
therefore of importance to describe and understand
developmental programs, cellular responses to
internal or external cues, or human diseases. We
describe here a method, Pyrosequencing Analysis
of Splicing Patterns (PASP), that combines RT–PCR
and pyrosequencing of PCR products.
We demonstrated that: (i) Ratios of two pure RNAs
mixed in various proportions were accurately mea-
sured by PASP; (ii) PASP can be adapted to virtually
any splicing event, including mutually exclusive
exons, complex patterns of exon skipping or inclu-
sion, and alternative 3’ terminal exons; (iii) In extracts
from different organs, the proportions of RNA
isoforms measured by PASP reflected those mea-
sured by other methods. The PASP method is there-
fore reliable for analysing splicing patterns. All steps
are done in 96-wells microplates, without gel
electrophoresis, opening the way to high-throughput
comparisons of RNA from several sources.
INTRODUCTION
Gene expression in eukaryotes consists of several coupled
steps that take place in the nucleus and the cytoplasm.
The nucleus is the place where pre-mRNA are transcribed
from DNA matrices and matured to mRNA. Maturation
consists of 50 end capping, 30 end cleavage and poly-
adenylation and removal of internal introns associated
with exons splicing. Furthermore, diﬀerent mRNAs can
be obtained from the same pre-mRNA due to a process
referred to as alternative splicing. In extreme cases, such as
Drosophila Dscam, several thousands of diﬀerent mRNAs
may be generated from a given pre-mRNA (1). The term
alternative splicing encompasses mutually exclusive
exons (where splicing leads to the inclusion of either of
two exons), exon skipping, intron retention, alternative 50
or 30 splice sites (leading to retention of all or only part of
an exon or an intron), or alternative initial or terminal
exons (2).
Alternative splicing is responsible for a considerable
variety of mature, cytoplasmic mRNAs, greatly expanding
the proteome. It is generally regulated in a cell or tissue-
speciﬁc manner, often during developmental programmes.
In addition to regulated alternative splicing, defects in
constitutive splicing may also generate some diversity
in mature mRNAs. These splicing defects may lead to
deleterious eﬀects. It is estimated that a large part (up to
50%) of the mutations causing human diseases alter
mRNA splicing (3).
These observations highlight the need for methods to
analyse mRNA-splicing patterns. A number of methods
have been published, and all of them have advantages and
limitations. Here, we sought to test if a quantiﬁcation of
alternative mRNA isoforms can be achieved by pyro-
sequencing. In contrast to dideoxynucleotide-based
methods for DNA sequencing, pyrosequencing is a quan-
titative method, in as much as the heights of the peaks
generated from pyrosequencing a mixture of several
DNAs are strictly proportional to the molar ratios of
these DNAs (4). These properties were used to develop
quantitative analyses on DNA, such as characterization
of methylation patterns (5,6) and determination of
Single Nucleotide Polymorphism (SNP) allele frequencies
in a population (7,8). Pyrosequencing also allowed mea-
surements of mRNA ratios after reverse-transcription,
for instance to demonstrate allele-speciﬁc transcript
expression of imprinted genes (9,10) or to compare gene
expression levels from diﬀerent sources following
sequence-tagged RT-PCR (11).
Pyrosequencing was used in a limited number of cases
to analyse splicing patterns. Exon 3 of human stimulatory
G protein Gas can be spliced or skipped. Furthermore,
there exists an alternative 30 splice site in intron 3, leading
to shortening of exon 4 by 3 nt. Consequently, two alter-
native 50 ends of exon 4 can be spliced to either exon 2
or exon 3, generating four splice isoforms. Frey et al.
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quantiﬁed these isoforms in human tissues by
pyrosequencing (12). Also in several tissues, Szafranski
et al. measured the frequencies of alternative 30 splice
sites usage by pyrosequencing (13). However, these two
articles did not examine other types of splicing events,
like mutually exclusive exons, alternative terminal
exons or consecutive alternative exons potentially leading
to complex patterns. We develop here a RT–PCR-
pyrosequencing based method that we termed Pyrose-
quencing Analysis of Splicing Patterns (PASP). PASP is
applicable to analysing virtually any splicing pattern.
Furthermore, the majority of the steps can be automated,
allowing several hundreds of splicing events to be analysed
within a limited time scale and in cost-eﬀective conditions.
MATERIALS AND METHODS
General biological and biochemical methods
Anatomical pieces from euthanized mice or Xenopus were
harvested in liquid nitrogen. Total RNA was extracted
using Tri-Reagent (Euromedex). Animals were treated fol-
lowing European rules for animal welfare. Xenopus
embryos were obtained by in vitro fertilization following
standard procedures.
Pure RNA containing either the 6A or the 6B exon of
the Xenopus a-tropomyosin gene were obtained by in vitro
transcription (Promega) from the XTMa24 and XTMO54
plasmids (14) and mixed in various proportions. Pure
RNA or RNA extracted from animal organs or embryos
were reverse-transcribed using random primers (except
30RACE), 0.5mM dNTP and Superscript II Reverse
Transcriptase (Invitrogen) following standard procedures.
For 30RACE, reverse transcriptions were made with using
an anchored oligo(dT) primer (GGCCAGGGTTTTCCC
AGTCACGACT16V, V=A, C or G) as described (15).
For radioactive analysis of splicing patterns, the a-
tropomyosin forward primer (sequence CAGAGGAAC
GTGCTGAACTTT) was radiolabelled using T4 poly-
nucleotide kinase (Promega) and g32P-ATP. cDNAs
were ampliﬁed using that radiolabelled forward primer
and a reverse primer (sequence ATTTGTCCTCCTTCT
GGGAGTA) with the following program: 90 s at 948C,
then (1min at 948C, 30 s at 588C, 30 s at 728C) for 30
cycles. The resulting PCR mixtures were divided into
three parts, one of which was directly electrophorized on
12% polyacrylamide gels, and the two other parts were
digested with BstNI or AvaII before electrophoresis.
Dried gels were submitted to STORM Phosphorimager
(Molecular Dynamics) analysis and quantiﬁed with the
Imagequant software.
Pyrosequencing
PCR and sequencing primers were designed using the PSQ
assay design software and purchased from Sigma Proligo
or Eurogentec. The PCR conditions were the same as
above except for the number of cycles. The sequences of
PCR and sequencing primers are given in Table 1.
Pyrosequencing was done following the instructions of
the manufacturer of the pyrosequencing device
(Biotage). Brieﬂy, the resulting amplimeres were bound T
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to agarose–streptavidin beads (GE Healthcare) for 15min
under continuous agitation. Beads were loaded on the
Biotage Workstation under vacuum for successive
treatments with 70% ethanol, alkaline denaturation
buﬀer and neutralization buﬀer. Finally, beads were
resuspended in the pyrosequencing plate in wells
containing 0.4mM of sequencing primer and heat-
denatured (2min, 858C). The content of the plate was
pyrosequenced on a Biotage PSQ 96 MA device and
analysed using the Pyromark software. The nucleotide
dispensation order and the formulae used to calculate
the percentages of the diﬀerent isoforms are given in
Table 1.
RESULTS
Principe of analysis of splicing pattern by pyrosequencing
The ﬂow chart of the PASP method is shown in Figure 1.
Total RNA is extracted and reverse-transcribed following
standard procedures. The cDNAs are PCR-ampliﬁed
using primers complementary to conserved regions
ﬂanking the alternative-splicing event to be analysed
(indicated by alternative-splicing event 1 or 2 on
Figure 1). This results in a mixture of DNAs whose
relative proportions are related to those of the initial
mRNA pool. These proportions can be measured by
pyrosequencing as would be done in a SNP analysis by
determining, for a population of molecules, the relative
proportions of each nucleotide at a given genomic
position. Brieﬂy, correct ampliﬁcation can be checked by
native electrophoresis (but this is not always necessary, see
below). Next, PCR products are bound to streptavidin
beads via the biotin moiety that is present at the 50 end
of one of the PCR primers. Bound PCR products are
denatured by alkaline treatment. A sequencing primer
is then annealed to the resulting single-stranded DNA
fragment bound to the beads. This primer must be
designed to hybridize to a region that is conserved between
all the PCR products, but should be adjacent (1–3 nt) to
the alternative region. Finally, pyrosequencing is done
using a nucleotide dispensation order permitting cal-
culations of the relative proportions of the alternative
PCR products (see examples below), using software
dedicated to SNP analyses. Importantly, most of the
PASP steps can be automated, greatly increasing
throughput.
Mutually exclusive exons
We decided to use the Xenopus a-tropomyosin mRNA to
provide a proof-of-principle of the method. Both exons
5 and 7 are constitutive, and two mutually exclusive
exons 6 (6A and 6B) contain the same number of
nucleotides despite diﬀerent sequences (Figure 2A) (14).
A method to determine the relative proportions of these
two exons within a population of mRNA is to run a PCR
using primers hybridizing in the exons 5 and 7, one of
which is radiolabelled, then to separate the PCR products
by electrophoresis and to analyse them by autoradio-
graphy. One such analysis is shown in Figure 2A, upper
panel. RNAs were obtained by in vitro transcription from
a-tropomyosin templates containing either the 6A or the
6B exon. These RNAs were mixed in various proportions.
After reverse transcription, they were PCR-ampliﬁed
using a forward 32P-labelled reverse primer. Due to the
fact that exons 6A and 6B have the same size, this yielded
a unique, 133-bp long, PCR product, irrespective of the
proportions of exons 6A and 6B (Figure 2B, upper panel).
To discriminate between the two PCR products, restric-
tion with AvaII or BstNI was used. The BstNI site is only
present in the 6B exon whereas the AvaII site is only pres-
ent in the 6A exon. Hence the proportions of BstNI-
restricted PCR product reﬂect those containing exon 6B
(middle panel) and the proportions of AvaII-restricted
PCR product reﬂect those containing exon 6A (lower
panel). The ratios of exons 6A to 6B in the populations,
calculated from the proportions of the diﬀerentially
restricted cDNAs, were in close agreement with the
expected ratios (Figure 2C). Very similar results were
obtained when 10 times or 100 times more RNA were
used as RT–PCR matrices (data not shown).
For the PASP method, cDNAs were PCR-ampliﬁed
using a biotinylated forward primer complementary to
RT-PCR using primers flanking the alternative 
splicing event with one biotinylated primer
1
2 (Optional) Check PCR product by native
gel electrophoresis
3 The biotinylated PCR products are bound onto
streptavidin beads. DNA is denaturated and 
annealed to a sequencing primer
4 Pyrosequencing using the approprate
dispensation order of nucleotides to
generate a pyrogram
5 The relative proportions of the alternative PCR
products are deduced from analyses of the
pyrograms using SNP-dedicated softwares
pre-mRNA
s
b
b rev primerbiotinylated
fwd primer
AS1 or AS2
Alternative splicing
 event 1
Alternative splicing
 event 2
const. ex. const. ex. const. ex. const. ex.AS1 AS2
AS1 or AS2
Figure 1. Flow-chart of the PASP method. See text for details.
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exon 5 and a reverse primer complementary to exon 7
(Figure 2D). The PCR products were pyrosequenced
using an antisense sequencing primer (s) complementary
to the 50 end of exon 7 (just 30 of the 6A or 6B exon). With
this primer, the beginning of the sequence read from a 6A
matrix would be CTCTTCTGA, whereas that from a 6B
matrix would be CTCTGCCTG. The dispensation order
and typical pyrograms, corresponding to diﬀerent
percentages of exon 6B, are shown in Figure 2D. The
ﬁrst dispensed nucleotide (A1) is present in neither of
the two sequences, and was used to estimate the back-
ground signal. The following three nucleotides (C2, T3
and C4) are present in both isoforms. As expected, they
were detected at similar levels irrespective of the
A
5 7
5 7
5 7
pre-mRNA
6A
6B
C
0
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80
100
0 20 40 60 80 100
Calculated from AvaII restriction
y=1.057x; R2=0.9615
C
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te
d 
6B
%
Initial 6B%
B
6B% 1 2 50 10 20 50 80 90 95 98 100
*
-133
-133
-66
A
B
66
94
-94
-133
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*
*
*
B
A
Not cut
BstNI
AvaII
6A
6B
6B
6B6A
6A
6B
6A
0
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100
0 20 40 60 80 100
C
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te
d 
6B
%
Initial 6B%
Calculated from BstNI restriction
y=1.0597x; R2 = 0.9751
Nt number               1    2   3   4    5   6   7   8   9   10
Disp. order    E   S  A   C   T   C   T   C  G  T   G   C
incorp in 6A            -    +    +   +  ++  +   -   +   +    -
incorp in 6B            -    +    +   +   +    -   +   -    -   ++
E
Initial 6B%
0 20 40 60 80 100
0
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100
C
al
cu
la
te
d 
6B
%
Calculated by PASP
y=0.9959x; R2 =0.9554
D 6A or 6B s revb
fwd
75
(3') GTCCG CTC <TTCATGAGGGTCTTCCT (5') 6B
(3') AGTCTT CTC <TTCATGAGGGTCTTCCT (5') 6A
100% 6A
E
S
C CT
TT
C T G
50% 6B
50%6A
E
S
C CT
T+TT
2
C
2 G
2
T
2 G2
CC
2
100% 6B
C T C T G
CC
S
E
Figure 2. Comparison of radioactive and PASP methods to analyse splicing patterns of two mutually exclusive exons. (A) Schematic of Xenopus
a-tropomyosin pre-mRNA and the two alternative mature isoforms (6A and 6B). Exons are represented by boxes and introns by lines. (B) RNAs
containing either the exon 6A or the exon 6B of Xenopus a-tropomyosin were obtained by in vitro transcription and mixed in the indicated
proportions (6B%). In all mixes, the total amount of RNA was 1 ng. RNAs were reverse-transcribed using random primers and PCR-ampliﬁed
using a radiolabelled (as indicated by the star) forward primer complementary to exon 5 and a reverse primer complementary to exon 7. One-third of
the PCR products was electrophoresed in a native acrylamide gel (upper panel), and the other two-thirds were digested by either BstNI or AvaII
before electrophoresis (middle and lower panels, respectively). On the sides of the gels are indicated the positions of the restriction sites BstNI (B, in
exon 6B) and AvaII (A, in exon 6A) as well as the sizes of the radiolabelled restriction fragments. (C) The percentages of exon 6B calculated from the
proportion of DNA left intact after AvaII restriction (upper panel) or cut by BstNI (lower panel) were plotted versus the proportion of exon 6B in
the initial RNA mixture. (D) Positions of the biotinylated forward (fwd), reverse (rev) and sequencing (s) primers used for PASP of a-tropomyosin.
Exons 6A and 6B are in light and dark grey, respectively. Inverse complementary of the sequencing primer is underlined (note that 50–30 orientation
is from right to left). Boxed CTC is a trinucleotide that is present in both 6A and 6B PCR products and is immediately downstream of the
sequencing primer. Three representative pyrograms corresponding to the indicated proportions of 6A and 6B RNA are shown with the nucleotide
(Nt) dispensation order. E and S stand for enzyme and substrate, respectively. (E) One nanogram of total RNA containing various proportions of
6A and 6B isoforms was reverse transcribed, PCR ampliﬁed for 35 cycles, and submitted to PASP analysis. The proportions of exon 6B calculated
from the ratios of peak heights in pyrograms [100G7/(G7+G9)] were plotted versus the proportions of exon 6B in the initial RNA mixture.
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percentage of 6B. Nucleotides 5–10 discriminate between
the two isoforms (Figure 2D).
Peak heights of the pyrograms, as provided by the
Pyromark software, were used to calculate the percentages
of 6B mRNA. The yields of the diﬀerent nucleotides were
not exactly the same. For example, in Figure 2D, the peak
for T3 is slightly smaller than the peaks for C2 and C4,
although these three peaks correspond to constitutive
nucleotides and should be similarly incorporated. Since
these diﬀerences might introduce a bias if diﬀerent
nucleotides were used to calculate isoforms ratios, we
used the same nucleotide that is present in both isoforms
at diﬀerent positions for the calculations. G7 and G9
correspond to the 6B and 6A isoforms respectively
(Figure 2D), hence the percentage of 6B equals to 100
G7/(G7+G9). Figure 2E demonstrates a close agreement
between the percentage of 6B calculated by this method
and the percentage of 6B in the initial RNA mixture.
Furthermore, the PASP results from 30 or 35 PCR
cycles were indistinguishable, as well as the results
obtained from various initial amounts of mixed mRNAs
(data not shown), showing that the PASP method is
largely insensitive to variations in these reaction
conditions. Comparison of Figures 2C and 2E indicates
that the radioactive and PASP methods are equally precise
in quantifying the proportions of mutually exclusive exons
in a population.
In order to reduce the time of the PASP analysis, we
evaluated whether checking the PCR ampliﬁcation by gel
electrophoresis was mandatory. We observed that ineﬃ-
cient PCR ampliﬁcations, resulting in too low an amount
of product to be sequenced, yielded low-quality pyro-
grams, and incorrect estimations of the 6B percentage
(data not shown). To eliminate the electrophoresis step,
we therefore developed quality controls of the pyrograms
so as to be able to discard potentially non-reliable results
due to bad ampliﬁcations. We examined the predictive
values for reliable results of two putative quality controls
(QC). As a ﬁrst quality control (QC1), we examined the
height of the ﬁrst constitutive nucleotide (C2), reasoning
that a high peak value should reveal a large amount of
ampliﬁed DNA. Quality control 2 (QC2) was calculated as
the ratio between C2 and A1 (respectively, ﬁrst constitu-
tive nucleotide and nucleotide absent from the two
isoforms). This ratio was expected to correspond to a
signal/noise ratio; hence it should be as high as possible.
To determine the values of QC1 and QC2 relative to the
quality of PCR ampliﬁcation, PCR were performed on
mixtures of 6A and 6B RNA either with (Figure 3, lanes
1–3, 5–7 and 9–11) or without (lanes 4, 8 and 12) previous
reverse-transcription. As expected, correct PCR products
were present only in the presence of reverse-transcriptase
(Figure 3). When PCR products were present, the values
for QC1 (strength of signal), were above 40, and the values
for QC2 (signal/background) were above or close to 100.
In contrast, when ampliﬁcation failed, QC1 values were
less than 1, and QC2 values were no more than 14. Several
experiments correlated correct ampliﬁcations (as tested by
gel electrophoresis) with high QC1 and QC2 values (data
not shown). We found that values higher than 40 and
80 for QC1 and QC2, respectively, accurately reﬂected
correct ampliﬁcations and PASP. Hence, checking PCR
by gel electrophoresis can be replaced by adequate QCs
of PASP.
The above results were obtained from mixes of pure
RNAs produced by in vitro transcription. It was important
therefore to check that the PASP method also applies to
complex RNA mixtures extracted from cells or tissues.
It was shown previously that exon 6A is essentially
retained in mRNA transcribed in oocytes, whereas exon
6B is essentially retained in embryonic somite (presum-
ptive muscles) or adult skeletal and cardiac muscle (14).
By PASP, oocytes and early embryos (Stage 8) were found
mainly to express a 6A isoform, whereas adult heart, skel-
etal muscle or stomach, or whole late embryos (Stage 35)
and dissected somites were found to express mainly a 6B
isoform. An intermediate situation was found for oviducts
that contain muscles but are frequently contaminated by
oocytes (Figure 4, upper panel). These results were similar
to those obtained by radioactive RT–PCR (Figure 4,
lower panel) and to previous data (14).
Complex combination of exons skipping and inclusion
Mutually exclusive exons are only part of the alternative-
splicing events that can occur on a pre-mRNA. One char-
acteristic is that they may produce alternatively spliced
products that have the same size (if the mutually exclusive
exons have the same size, as for exons 6A and 6B of
Xenopus a-tropomyosin). In contrast, splicing products
of diﬀerent sizes are obtained from other alternative-
splicing events [exon skipping, intron retention, alternative
50 or 30 sites (2)]. In addition, more than two isoforms
can be produced by alternative splicing. We evaluated
therefore whether the PASP method could apply to
these complex-splicing events. We choosed murine Tnnt2
(troponin T type 2, also named cTNT for cardiac troponin
T) as a model to test this issue. Two constitutive exons
(3 and 6) ﬂank two alternative exons (4 and 5). In muscu-
lar cells, each alternative exon can be either included or
skipped, so that four isoforms of diﬀerent sizes can be
obtained from the same pre-mRNA (Figure 5A) (16).
1 2 3 4
1ng
5 6 7 8 9 10 11   12
RNA
6B%
RT
QC1    40.4    43.9    42.4   0.76    58.6    62.5    64.3    0.7    56.2     56.4   57.8    0.85
QC2     96      116     177      4        225     174     157      3      156      149    126      14
10 ng 100 ng
0 50 100 50 0 50 100 50 0 50 100 50
+ + + – + + + – + + + –
Figure 3. Quality controls of PASP. RNAs containing exons 6A or 6B
were mixed in the indicated proportions (6B%) to a total amount of 1,
10 and 100 ng and reverse-transcribed, except for lanes 4, 8 and 12
where the reverse transcriptase was omitted. The resulting cDNAs
were PCR-ampliﬁed for 25 cycles in a total volume of 50 ml. Five
microlitres of the PCR products were electrophorised on a native
agarose gel in the presence of Syber-Green and the gel was
photographed. The remaining PCR products were submitted to PASP
with the same dispensation order as in Figure 2D. QCs 1 and 2
were calculated as described in text and the values are given below
each lane.
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For PASP analysis, total RNA extracted from mouse
heart or skeletal muscle was reverse-transcribed, PCR-
ampliﬁed using a biotinylated reverse primer, and
pyrosequenced using two diﬀerent sequencing primers
(Figure 5A). Sequencing primer s1 hybridizes to exon 3.
It allows sequencing of the exon spliced 30 to exon 3 and
discriminates between isoforms 4+9 (exon 4), 5 (exon 5)
and ref (reference, exon 6). It does not discriminate
between isoforms 4 and 9, which is achieved by sequencing
primer s2. Organs from three diﬀerent mice (adults or
foetuses) were analysed. Results of pyrosequencing using
primers s1 and s2 are shown in Figure 5B, left and middle
panels, respectively. The percentages of each of the four
isoforms were calculated from these series of data (right
panel). The results obtained from the three diﬀerent mice
were very similar, and average values were calculated
(Figure 5C). These results show that, whereas the splicing
patterns in skeletal muscle and heart are similar, the per-
centages of alternative exons inclusion strongly decreased
between embryos and adults. Inclusion of exon 5
decreased more than 3-fold (from 22.2 and 31.3% down
to 5.3 and 9.1% in heart and muscle, respectively). A
similar decrease in exon 5 inclusion has already been
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Figure 5. PASP analysis of Tnnt2 splicing in mice. (A) Schematic drawing of mouse Tnnt2 pre-mRNA and of the alternative isoforms of Tnnt2
mRNA. The positions of the primers for pyrosequencing are shown. Primer s1 hybridizes in the constitutive exon 3 and sequences either exon 4
(isoforms 4 and 9), exon 5 (isoform 5) or constitutive exon 6 (isoform ref, reference). Primer s2 hybridizes in exon 4 and sequences either exon 5 or
exon 6, hence it discriminates between isoforms 4 and 9. (B) PASP of Tnnt2 in the hearts or the skeletal muscles of three diﬀerent adult or foetal
mice using primer s1 or s2 as indicated (two left panels). The right panel (s1+ s2) combines the data shown in the two left panels to calculate the
percentages of the four Tnnt2 isoforms. (C) Mean SD values were calculated from the above data. Inclusion of exon 4 corresponds to isoforms
4 and 9, and inclusion of exon 5 corresponds to isoforms 5 and 9.
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Figure 4. PASP of a-tropomyosin in Xenopus embryos and organs.
RNAs were extracted from oocytes, stage 8 or 35 embryos, dissected
embryonic somites or the indicated adult organs, and a-tropomyosin-
splicing patterns were analysed by PASP. The percentages of exon
6B (mean SD of six independent RNA preparations) are shown
(upper panel). Adult heart, oviduct stomach, and oocyte RNA were
also analysed by radioactive RT–PCR as in Figure 2B (lower panel).
The percentages of 6B exon (restricted by BstNI) are indicated under
the gel.
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observed (16). Consequently, PASP analysis successfully
reproduced results obtained with other methods.
Alternative 3’ terminal exons
We next used PASP to analyse alternative 30 terminal
exons. In this case, there is no constitutive exon 30 to the
alternative-splicing event that can be targeted by a PCR
primer. In 30RACE, reverse transcription is made with an
oligo(dT) primer containing an additional 50 extension
(‘anchor’). Next, a primer corresponding to the anchor
is used together with a gene-speciﬁc primer for PCR
(15). To test 30RACE-PASP on Xenopus a-tropomyosin
mRNA, we made RTs using RNAs from several diﬀerent
Xenopus tissues with an oligo(dT)-anchor, then a PCR
with a biotinylated anchor and a forward primer speciﬁc
for a-tropomyosin exon 8 (Figure 6A). a-Tropomyosin
mRNA may have three diﬀerent terminal exons as
depicted in Figure 6A (17). We used two sequencing
primers to discriminate between the three diﬀerent
isoforms. Primer s1 hybridizes in exon 8 and discriminates
O5 versus a2 and a7, s2 hybridizes in exon 9A and
discriminates a2 versus a7.
Results obtained with sequencing primer s1 are shown
in Figure 6B, left panel. Striated muscles, as well as
embryos and embryonic somites, mainly spliced exon
9A90 to exon 8. In contrast, in stomach, isoform O5 was
clearly predominant. Results of sequencing with primer s2
(Figure 6B, middle) showed a diﬀerence between adult
organs that produced mainly a2, and embryonic organs
that produced a7. Due to the small amount of exon 9A
(binding site for primer s2) in stomach, the sequencing
using primer s2 failed and it was not possible to
discriminate a2 from a7 isoforms in that organ.
Combining the analyses with s1 and s2 (right panel)
showed that the main isoforms were O5 in stomach, a2
in adult striated muscles and a7 in embryos, again consis-
tent with previous results (17).
DISCUSSION
Several methods aimed at analysing splicing patterns have
been published. Northern blotting may be considered
if the isoforms to be discriminate have suﬃciently diﬀerent
sizes to be resolved by electrophoresis. An advantage
of northern blotting is that the RNA to be analysed are
directly detected, avoiding ampliﬁcation bias that may
arise with PCR. However, this approach is virtually no
longer used due to a very limited sensitivity (it requires
ten to several tens mg of total RNA), and an incapacity
to analyse splicing events that lead to isoforms of similar
sizes. RNase protection assays (RPA) share with northern
blotting the lack of requirement for ampliﬁcation. The
sensitivity of RPA is better than that of northern,
although still low (it requires 1–10 mg of total RNA),
and RPA is able to analyse more subtle splicing patterns
[for instance (18)]. However, the method is time-
consuming. Among non-automatable steps, it requires
synthesis of labelled RNA probes, hybridization and
RNase treatment, gel electrophoresis and drying, and
quantiﬁcation of radioactive signals by densitometry
or from phosphorimager ﬁles. Furthermore, due to
the extreme reactivity of RNase, this assay cannot be
used to screen for splicing patterns in diﬀerent samples
with genetic variations including single nucleotide
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Figure 6. Combined PASP and 30RACE to analyse splicing of alternative 30 terminal exons. (A) Schematic drawing of the 30 terminal part of
Xenopus a-tropomyosin pre-mRNA. Constitutive exon 8 can be spliced to exon 9D to generate isoform O5. Alternatively, it can be spliced to exon
9A90. Exon 9A90 can be used as the terminal exon (yielding isoform a7) or can be spliced to exon 9B via an alternative internal 50 splice site to create
isoform a2. In 30RACE-PASP, an anchored oligo(dT) primer is used for RT, and a biotinylated reverse oligonucleotide corresponding to the anchor
is used for PCR together with a forward primer in constitutive exon 8. Sequencing primer s1 hybridizes within constitutive exon 8, to discriminate
between exon 9D, isoform O5, and 9A, isoforms a2 plus a7. Sequencing primer s2 hybridizes within exon 9A, to discriminate between exon 90,
isoform a7, and 9B, isoform a2. (B) 30RACE-PASP of a-tropomyosin in the indicated tissues. Shown are the results obtained using sequencing
primers 1 and 2 (mean SD of three diﬀerent animals), and the results calculated from combining these two sequencings.
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polymorphism. Invader RNA assays rely on the detection
of a cleaved DNA probe that occurs when hybridized to a
complementary RNA. Consequently, using a set of DNA
probe corresponding to the sequences of the diﬀerent
isoforms, it is possible to quantify these isoforms (19).
However, this is not amenable to analyses of numerous
splicing patterns.
The most widely used methods are real-time and end-
point RT–PCR. Real-time RT–PCR is nowadays the best
method to quantify RNA levels, due to its unequalled sen-
sitivity and the facility to simultaneously analyse several
targets. However, in its simplest (and cheapest) design,
that is with a ﬂuorescent DNA intercalating dye, only
one ampliﬁcation product can be quantiﬁed with a given
pair of primers. Consequently, to analyse alternative-
splicing patterns, it is necessary to design several primer
pairs, each of them being speciﬁc for one mRNA isoform
(20,21). To accurately measure the isoform ratios, it is
therefore necessary to use primer pairs with the same
ampliﬁcation eﬃciencies, which is often diﬃcult to
achieve. In contrast, in end-point PCR, it is generally pos-
sible to use only one pair of PCR primers to amplify all
the isoforms, and to individually quantify the isoforms.
For example, if one of the PCR primers is radiolabelled,
the PCR products are easy to detect and quantify after
electrophoresis by autoradiography or preferably phos-
phorimager analysis. On the basis of diﬀerential
electrophoretic mobilities, it may be possible to directly
discriminate between the PCR products derived from the
diﬀerentially spliced mRNAs. This method can be used
for the analysis of splicing of both endogenous mRNAs
and recombinant RNAs transcribed from a minigene [e.g.
see (18)].
PASP shares with RT–PCR the advantage of being very
sensitive. Furthermore, since only one pair of primers is
used to amplify all the isoforms, its eﬃciency does not
need to be carefully controlled. Finally, several kinds of
splicing event can be detected by radioactive RT–PCR or
PASP: the presence of either of two sequences (mutually
exclusive exons), the presence or the absence of one
sequence (exon skipping, intron retention, alternative 50
or 30 sites) or diﬀerent 30 mRNA extremities (alternative
terminal exons). Pyrosequencing was previously used in a
limited number of cases to analyse splicing patterns
(12,13), but neither of these articles examined the capacity
of RT–PCR-pyrosequencing to measure the ratios of
isoforms that originate from this variety of splicing
events. The possibility to use two sequencing primers to
analyse complex-splicing patterns was also not investi-
gated in these articles. However, PASP has several
additional advantages over radioactive RT–PCR. First,
no radioactive isotope is required. Second, it is much
more rapid, since all steps are performed in 96-wells
plates. Even gel electrophoresis is dispensable if the cor-
rect quality controls are used. Starting from cDNAs, the
time required to generate a raw data ﬁle corresponding to
one plate is about 4 h. Since three diﬀerent devices are
used (thermocycler, workstation for binding of ampli-
meres to streptavidin and treatments, pyrosequencer), it
is possible to treat several plates within the same working
day, allowing several hundreds of splicing events to be
analysed, or to fractionate the experiments into diﬀerent
days. A considerable increase in throughput is possible by
automating all of these steps.
A challenger to PASP is non-radioactive RT–PCR
followed by detection of the amplimeres by capillary
electrophoresis. This technology was used at a medium-
throughput level to identify splicing signatures of ovarian
cancer (22). However, as for radioactive RT–PCR,
analysing splicing patterns by RT–PCR capillary electro-
phoresis requires that all the isoforms have diﬀerent sizes,
a requirement that does not hold for PASP. Furthermore,
the isoforms are identiﬁed only by their electrophoretic
mobilities in RT–PCR capillary electrophoresis, whereas
they are identiﬁed by sequencing in PASP. This adds an
additional level of speciﬁcity that is valuable if some
aspeciﬁc PCR ampliﬁcation occurred.
A high-throughput method to analyse splicing patterns
is with splicing arrays. Initially, the oligonucleotides
spotted on the chips were designed so as to hybridize to
exon–exon junctions. Consequently, a positive signal was
detected for a given spot only if the tested sample included
mRNAs that were subject to the corresponding splicing
event (23). The determination of probes was based on the
characterization of gene exons from known mRNA.
Hence, exon boundaries must be known initially and if a
mRNA sequence has not been determined, exons will be
missed. Furthermore, the diﬀerences in melting tempera-
ture between probes and the cross-hybridization that are
likely to occur at junction probes have to be included in
the analysis. Other array designs include the use of probes
to target the internal part of constitutive and alternative
exons (24–27). A very high-density human ‘exon array’
has been developed by Aﬀymetrix and most global anal-
yses rely on the estimation of the relative abundance of
each exon (28). These chip-based technologies provide val-
uable information on the frequency of alternative-splicing
event and exon usage in a quantitative manner and may
also lead to the discovery of new splicing events. These
approaches allow the simultaneous analysis of thousands
of splicing events that may occur within a given mRNA
population and that must subsequently be validated. An
alternative to microarrays for genome-wide analyses of
splicing patterns is deep-sequencing of mRNAs within a
population (2,29).
However, due to the cost of either of these two methods,
only a limited number of diﬀerent RNA populations can
be tested. In this respect, PASP is complementary to exon-
junctions arrays or deep sequencing. These latter methods
allow hundreds of thousands of splicing events to be
simultaneously analysed in a RNA population, whereas
PASP may compare the splicing patterns of several
mRNAs from a large number of diﬀerent origins. For
example, with PASP one could compare several organs
with diﬀerent genetic backgrounds, make precise time-
course experiments, or rapidly screen for potentially
abnormally spliced RNAs in human patients or model
animals. PASP provides detailed knowledge about the
abundance of individual alternative-splicing transcripts
and the possibility to combine this technology with micro-
array analysis will be of great value in establishing varia-
tions in alternative-splicing among diﬀerent individuals
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that could have medical implications such as resistance to
drug or disease susceptibility.
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